Recordati Rare Diseases
As of the edition of 20 October 2026, Recordati Rare Diseases runs 17 drugs, 17 of them marketed; it is on route A at 0 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 17 |
| Total | 17 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ibuprofen | none listed | 11 |
| Asparaginase | Ended 1990 (computed from the first US licence) | 0 |
| Indomethacin | none listed | 3 |
| Pasireotide | Ends 2026 (patent) | 0 |
| Dactinomycin | none listed | 0 |
| Siltuximab | Ended 2026 (computed from the first US licence) | 2 |
| Amino acids | none listed | 0 |
| Cysteamine | none listed | 0 |
| Betaine | none listed | 2 |
| Osilodrostat | Ends 2033 (patent) | 0 |
| Mechlorethamine | none listed | 0 |
| Carglumic acid | Ends 2028 (exclusivity) | 0 |
| Succimer | none listed | 0 |
| Hemin | Ended 1995 (computed from the first US licence) | 0 |
| Sutimlimab | Ends 2034 (computed from the first US licence) | 2 |
| Tocofersolan | none listed | 0 |
| Ethotoin | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 6 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where Recordati Rare Diseases needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.